Observational Study of Liposomal Amphotericin B for Treating Breakthrough Invasive Fungal Disease in Children and Adolescents with Blood Cancers on Antifungal Prophylaxis

What this Trial Is About

Researchers are evaluating the efficacy and safety of liposomal amphotericin B L-AmB for treating breakthrough invasive fungal disease br-IFD in Chinese children and adolescents with blood cancers who are receiving antifungal prophylaxis with triazoles or echinocandins. The study aims to compare response rates and kidney safety in this younger group with historical adult data to better understand L-AmBs role in pediatric care. This is a single-center, prospective, observational study where eligible children and adolescents diagnosed with br-IFD receive L-AmB as part of their standard antifungal treatment. Combination or sequential therapy with other antifungal drugs may be used as needed based on disease severity and immune status, and surgical treatment may be considered if appropriate. Medication dosing follows established guidelines. Participants will be monitored throughout treatment, typically lasting around two weeks, to evaluate their response, defined as complete or partial remission. Safety data, including kidney function, will also be collected during this period. The study plans to enroll about 43 patients to ensure sufficient data. All treatments and observations are recorded as part of regular medical care to assess outcomes in this population.

A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis